FarmaMondo Group Appoints Natalie Douglas as Independent Board Member to Enhance Market Access Strategies
The FarmaMondo Group, a global pharmaceutical distribution company, has officially appointed Natalie Douglas as an independent member of its board of directors. Douglas is celebrated for her leadership in global 'Managed Access' strategies and pharmaceutical marketing, making her a significant addition to the FarmaMondo team.
Based in Princeton, New Jersey, FarmaMondo operates in over 50 emerging markets in close collaboration with pharmaceutical and biotech firms to deliver innovative and specialized medicines. The company's strategic decision to bring Douglas on board underscores their commitment to enhancing patient access to life-saving therapies across diverse regions.
Douglas is notably recognized for pioneering the 'Managed Access to Commercialization' program, which provides a structured pathway for accessing numerous international markets. After her successful tenure in leadership roles at Johnson & Johnson (JJ), she founded IDIS, a specialized pharmaceutical organization renowned for its impressive portfolio of Managed Access programs. Under her stewardship, IDIS became a global leader, successfully executing more than 200 access programs for severe and rare diseases on behalf of over 40 pharmaceutical and biotech companies. The company was eventually acquired by Clinigen Group, validating the transformative commercial value of Douglas's contributions.
Yaron Spigel, CEO of FarmaMondo, commented, "Natalie Douglas is a prominent figure in the field of global patient access. Her innovation in Managed Access programs has set the industry standard and has helped connect pharmaceutical companies with healthcare facilities in hard-to-reach areas worldwide. Her joining our board is crucial as we expand partnerships with U.S.-based pharma and biotech firms aiming to comprehensively serve patients globally."
In light of rapid market expansion, FarmaMondo is experiencing pivotal growth. With 14 regional subsidiaries and a comprehensive portfolio featuring oncology, specialty medicines, and rare diseases, the company is committed to enhancing patient access globally. Douglas’s extensive experience aligns perfectly with FarmaMondo’s goal of improving the U.S. market presence.
"I am honored to bring my global market access expertise to FarmaMondo and to contribute to the company’s efforts in expanding its U.S. presence," expressed Natalie Douglas. She noted her admiration for the innovative approach the FarmaMondo team has taken in advancing the model for international market access. "The work FarmaMondo is doing with its pharma partners resonates with my passion for helping patients who desperately need life-changing medications, especially those living outside the traditional geography of large markets."
FarmaMondo Group is a pharmaceutical company dedicated to providing a turnkey integrated market presence in over 50 emerging countries – from early market access to commercialization – ensuring that vital medications reach patients in need. By improving access to life-altering therapies across numerous specialties, including oncology, hematology, endocrinology, neurology, and metabolic disorders, FarmaMondo is steadfast in its commitment to making transformative therapies accessible to patients worldwide.
Media Contact:
Ivy Cohen
Ivy Cohen Corporate Communications
+1 (212) 399-0026
[email protected]
This strategic appointment of Natalie Douglas is expected to bolster FarmaMondo’s initiatives towards making essential medications available to even more patients around the globe, ensuring that all individuals, regardless of their location, have access to life-saving treatments.
Based in Princeton, New Jersey, FarmaMondo operates in over 50 emerging markets in close collaboration with pharmaceutical and biotech firms to deliver innovative and specialized medicines. The company's strategic decision to bring Douglas on board underscores their commitment to enhancing patient access to life-saving therapies across diverse regions.
Douglas is notably recognized for pioneering the 'Managed Access to Commercialization' program, which provides a structured pathway for accessing numerous international markets. After her successful tenure in leadership roles at Johnson & Johnson (JJ), she founded IDIS, a specialized pharmaceutical organization renowned for its impressive portfolio of Managed Access programs. Under her stewardship, IDIS became a global leader, successfully executing more than 200 access programs for severe and rare diseases on behalf of over 40 pharmaceutical and biotech companies. The company was eventually acquired by Clinigen Group, validating the transformative commercial value of Douglas's contributions.
Yaron Spigel, CEO of FarmaMondo, commented, "Natalie Douglas is a prominent figure in the field of global patient access. Her innovation in Managed Access programs has set the industry standard and has helped connect pharmaceutical companies with healthcare facilities in hard-to-reach areas worldwide. Her joining our board is crucial as we expand partnerships with U.S.-based pharma and biotech firms aiming to comprehensively serve patients globally."
In light of rapid market expansion, FarmaMondo is experiencing pivotal growth. With 14 regional subsidiaries and a comprehensive portfolio featuring oncology, specialty medicines, and rare diseases, the company is committed to enhancing patient access globally. Douglas’s extensive experience aligns perfectly with FarmaMondo’s goal of improving the U.S. market presence.
"I am honored to bring my global market access expertise to FarmaMondo and to contribute to the company’s efforts in expanding its U.S. presence," expressed Natalie Douglas. She noted her admiration for the innovative approach the FarmaMondo team has taken in advancing the model for international market access. "The work FarmaMondo is doing with its pharma partners resonates with my passion for helping patients who desperately need life-changing medications, especially those living outside the traditional geography of large markets."
About FarmaMondo Group
FarmaMondo Group is a pharmaceutical company dedicated to providing a turnkey integrated market presence in over 50 emerging countries – from early market access to commercialization – ensuring that vital medications reach patients in need. By improving access to life-altering therapies across numerous specialties, including oncology, hematology, endocrinology, neurology, and metabolic disorders, FarmaMondo is steadfast in its commitment to making transformative therapies accessible to patients worldwide.
Media Contact:
Ivy Cohen
Ivy Cohen Corporate Communications
+1 (212) 399-0026
[email protected]
This strategic appointment of Natalie Douglas is expected to bolster FarmaMondo’s initiatives towards making essential medications available to even more patients around the globe, ensuring that all individuals, regardless of their location, have access to life-saving treatments.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.